Search Results for "f"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for f. Results 111 to 120 of 858 total matches.

Bepotastine (Bepreve) - An Ophthalmic H1-Antihistamine

   
The Medical Letter on Drugs and Therapeutics • Feb 08, 2010  (Issue 1331)
., M.P.H., F.A.C.P., Harvard Medical School EDITOR: Jean-Marie Pflomm, Pharm.D. ASSISTANT EDITORS ...
Bepotastine besilate 1.5% ophthalmic solution (Bepreve - ISTA Pharmaceuticals), an H1-antihistamine, has been approved by the FDA for topical treatment of itching associated with allergic conjunctivitis in patients ≥2 years old. Bepotastine was first developed in an oral systemic formulation and has been used as such for treatment of allergic rhinitis in Japan.
Med Lett Drugs Ther. 2010 Feb 8;52(1331):11-2 |  Show IntroductionHide Introduction

Robotic-Assisted Laparoscopic Surgery

   
The Medical Letter on Drugs and Therapeutics • Jun 14, 2010  (Issue 1340)
., M.P.H., F.A.C.P., Harvard Medical School EDITOR: Jean-Marie Pflomm, Pharm.D. ASSISTANT EDITORS ...
The da Vinci Surgical System (Intuitive Surgical, Sunnyvale, CA) has become available in recent years for use in laparoscopic prostatectomy, gynecological procedures, general surgery, otolaryngology and cardiothoracic procedures.
Med Lett Drugs Ther. 2010 Jun 14;52(1340):45-6 |  Show IntroductionHide Introduction

Safety of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease (COPD)

   
The Medical Letter on Drugs and Therapeutics • May 31, 2010  (Issue 1339)
. EXECUTIVE EDITOR: Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School EDITOR: Jean-Marie ...
Two combinations of an inhaled corticosteroid with an inhaled long-acting beta2-agonist are approved by the FDA for use in patients with COPD: fluticasone/salmeterol (Advair Diskus) and budesonide/formoterol (Symbicort). A Medical Letter reader has questioned the safety of using corticosteroid inhalers in patients with this disorder. No single-agent inhaled corticosteroid inhaler is approved for this indication.
Med Lett Drugs Ther. 2010 May 31;52(1339):41-2 |  Show IntroductionHide Introduction

Pediarix - a Combined Vaccine for Infants

   
The Medical Letter on Drugs and Therapeutics • May 12, 2003  (Issue 1156)
Meinertz, M.D., University Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F ...
A new pentavalent vaccine (Pediarix - GlaxoSmithKline), licensed by the FDA for children 6 weeks to 7 years old, includes the antigens from vaccines already marketed against diphtheria, tetanus and pertussis (Infanrix) and hepatitis B (Engerix-B), and a new inactivated polio component.
Med Lett Drugs Ther. 2003 May 12;45(1156):37-8 |  Show IntroductionHide Introduction

Quizartinib (Vanflyta) for Acute Myeloid Leukemia (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 16, 2023  (Issue 1687)
. In addition to high-dose cytarabine. 4. If QTcF is ≤450 ms. Dose can be increased to 53 mg on day 15 ...
The FDA has approved the oral kinase inhibitor quizartinib (Vanflyta – Daiichi Sankyo) for use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy in adults with FLT3 internal tandem duplication (ITD)-positive, newly-diagnosed acute myeloid leukemia (AML).
Med Lett Drugs Ther. 2023 Oct 16;65(1687):e169-70   doi:10.58347/tml.2023.1687d |  Show IntroductionHide Introduction

Correction: The EarCheck Middle Ear Monitor

   
The Medical Letter on Drugs and Therapeutics • Aug 11, 2008  (Issue 1292)
. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University ...
The article in the July 14th issue contained an error in the last sentence of the last paragraph beginning on page 55. The instrument's reading is determined not by the degree of protrusion of the tympanic membrane, but rather by its mobility.
Med Lett Drugs Ther. 2008 Aug 11;50(1292):64 |  Show IntroductionHide Introduction

Correction: CT Colonography

   
The Medical Letter on Drugs and Therapeutics • Dec 15, 2008  (Issue 1301)
. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University ...
(Med Lett Drugs Ther 2008; 50:94) In table 1, "Invasive" should be "less" and "more" rather than "no" and "yes" for CT colonography and colonoscopy, respectively.
Med Lett Drugs Ther. 2008 Dec 15;50(1301):97-100 |  Show IntroductionHide Introduction

Laser Coronary Angioplasty

   
The Medical Letter on Drugs and Therapeutics • Jan 25, 1991  (Issue 836)
stenosis were successfully treated with direct laser angioplasty alone (F Litvak et al, Am J Cardiol, 66 ...
Percutaneous transluminal coronary angioplasty (PTCA), in which a balloon catheter distends the vessel at the site of obstruction (Medical Letter, 25:97, 1983), is now an established therapeutic option for treatment of patients with coronary artery disease, especially those with single-vessel disease. Major problems related to PTCA include acute occlusion during the procedure (usually caused by dissection), restenosis at the site of angioplasty, and inability to treat complete occlusions and long or ostial lesions. Some cardiologists have tried using lasers during PTCA to deal with these...
Med Lett Drugs Ther. 1991 Jan 25;33(836):7-8 |  Show IntroductionHide Introduction

Drug Treatment of Cardiac Arrest

   
The Medical Letter on Drugs and Therapeutics • Mar 20, 1992  (Issue 866)
, 1986; F Kette et al, Circulation, 81:1660, 1990). Hypertonic solutions such as sodium bicarbonate ...
Cardiac arrest may be due to tachyarrhythmias, bradyarrhythmias, or asystole. Without treatment, permanent damage to the cerebral cortex usually begins within five minutes and is complete in ten. After cardiopulmonary resuscitation (CPR) has been started and electrical defibrillation, when indicated, has been applied, drugs may help promote recovery.
Med Lett Drugs Ther. 1992 Mar 20;34(866):30 |  Show IntroductionHide Introduction

In Brief: Influenza Developments

   
The Medical Letter on Drugs and Therapeutics • Mar 24, 2008  (Issue 1282)
. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University ...
Recent reports (D Kaye.Clin Infect Dis April 1, 2008;46:iii) indicate that 2 of the 3 components of this year's influenza vaccine (Med Lett Drugs Ther 2007;49:81), the influenza B and A/H3N2 antigens, do not matchup well with circulating strains. The B component is probably not protective. The A/H3N2 antigen in the vaccine probably provides some protection, particularly for high-risk patients. The third component, the A/H1N1 antigen, is protective against circulating A/H1N1 influenza viruses, but these viruses, unlike previous A/H1N1 strains, are developing some resistance to oseltamivir...
Med Lett Drugs Ther. 2008 Mar 24;50(1282):21-4 |  Show IntroductionHide Introduction